Fusion Antibodies (LON:FAB) Stock Price Down 12% – Should You Sell?

Fusion Antibodies plc (LON:FAB)’s share price traded down 12% on Friday . The stock traded as low as GBX 6.22 ($0.08) and last traded at GBX 6.25 ($0.08). 3,481,229 shares changed hands during trading, an increase of 197% from the average session volume of 1,171,104 shares. The stock had previously closed at GBX 7.10 ($0.09).

Fusion Antibodies Price Performance

The company has a 50-day moving average of GBX 4.52 and a 200 day moving average of GBX 3.78. The company has a debt-to-equity ratio of 2.40, a quick ratio of 2.36 and a current ratio of 3.87. The firm has a market cap of £5.96 million, a P/E ratio of -177.50 and a beta of 0.49.

Insider Transactions at Fusion Antibodies

In other news, insider Adrian Kinkaid purchased 83,728 shares of the firm’s stock in a transaction that occurred on Wednesday, October 16th. The shares were acquired at an average price of GBX 4 ($0.05) per share, for a total transaction of £3,349.12 ($4,245.30). 11.39% of the stock is owned by company insiders.

Fusion Antibodies Company Profile

Fusion Antibodies plc, a contract research organization, engages in the research, development, and manufacture of recombinant proteins and antibodies primarily for cancer and infectious diseases in the United Kingdom, the rest of Europe, North America, and internationally. The company offers monoclonal antibody discovery and development, antibody sequencing, antibody engineering, antibody humanization and rational affinity maturation platform, recombinant protein expression, and stable cell line development and cGMP scale up services.